Finance

Lists
MDT:NYSE
Medtronic PLC
$94.17
+1.15%
(+1.07) 1D
Sep 4, 4:00:05 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MDT...
Open
$92.76
High
$94.74
Low
$92.31
Mkt. cap
120.54B
Avg. vol.
7.62M
Volume
0.00
Dividend
3.06%
Quarterly dividend
$0.72
Ex-dividend date
Sep 25, 2026
P/E ratio
23.18
52-wk high
$106.33
52-wk low
$73.31
EPS
$4.06
Beta
0.56
Shares outstanding
1.28B
No. of employees
95K
Open
$92.76
High
$94.74
Low
$92.31
Mkt. cap
120.54B
Avg. vol.
7.62M
Volume
0.00
Dividend
3.06%
Quarterly dividend
$0.72
Ex-dividend date
Sep 25, 2026
P/E ratio
23.18
52-wk high
$106.33
52-wk low
$73.31
EPS
$4.06
Beta
0.56
Shares outstanding
1.28B
No. of employees
95K
Profile
Medtronic plc is an American-Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies. It is one of the biggest medical tech companies in the world and is currently the largest medical device company in the world by revenue. The company has developed several world-first technologies since its inception, including wearable and implantable pacemakers, the implantable cardioverter-defibrillator, and remote patient monitoring systems. They also created miniaturized devices like the world's smallest pacemaker and spinal cord stimulator. Wikipedia
About Medtronic PLC
CEOGeoffrey S. Martha
Employees95K
Founded1949
Headquarters-
SectorMedical device
Analyst ratings
Based on 20 analysts giving stock ratings to MDT in the past 3 months
Buy
Buy
12
Hold
8
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for MDT in the last 3 months.
Highest
Current $94.17
$118.00 (+25.31%)
Average
$103.41 (+9.81%)
Lowest
$85.00 (-9.74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robbie Marcus
J.P. Morgan
Hold
Maintained
$96.00
+1.9%
09/03/2026
Pito Chickering
Deutsche Bank
Hold
Reiterated
$92.00
-2.3%
09/03/2026
Patrick Wood
UBS
Buy
Reiterated
$110.00
+16.8%
09/03/2026
Anthony Petrone
Mizuho Securities
Buy
Reiterated
$115.00
+22.1%
09/02/2026
Jayson Bedford
Raymond James
Hold
Maintained
-
-
09/02/2026
Matthew Taylor
Jefferies
Hold
Reiterated
$95.00
+0.9%
09/02/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$99.00
+5.1%
09/02/2026
Joanne Wuensch
Citi
Buy
Maintained
$110.00
+16.8%
09/01/2026
Kendall Au
RBC Capital
Buy
Reiterated
$118.00
+25.3%
09/01/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$118.00
+25.3%
09/01/2026
Rick Wise
Stifel Nicolaus
Hold
Maintained
$95.00
+0.9%
09/02/2026
David Rescott
Robert W. Baird
Hold
Maintained
$100.00
+6.2%
09/02/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$110.00
+16.8%
09/02/2026
Travis Steed
Bank of America Securities
Buy
Reiterated
$110.00
+16.8%
09/01/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$104.00
+10.4%
09/02/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/01/2026
Michael Matson
Needham
Buy
Reiterated
$114.00
+21.1%
09/01/2026
Ryan Zimmerman
BTIG
Buy
Reiterated
$100.00
+6.2%
09/01/2026
Matthew O'Brien
Piper Sandler
Hold
Maintained
$85.00
-9.7%
08/14/2026
Priya Sachdeva
UBS
Buy
Upgraded
$100.00
+6.2%
07/28/2026
Mike Kratky
Leerink Partners
Buy
Maintained
-
-
07/10/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$105.00
+11.5%
07/06/2026
David Roman
Goldman Sachs
Hold
Maintained
$83.00
-11.9%
06/04/2026
Lee Hambright
Bernstein
Buy
Maintained
$97.00
+3%
06/04/2026
David Toung
Argus Research
Buy
Maintained
$115.00
+22.1%
04/06/2026
Matt Miksic
Barclays
Buy
Maintained
$120.00
+27.4%
04/01/2026
Nico Chen
DBS
Hold
Maintained
$90.00
-4.4%
03/18/2026
Unknown Analyst
CICC
Buy
Initiated
$121.00
+28.5%
01/30/2026
Last report
Sep 1, 2026
Fiscal period
Q1 2027
EPS / Est. (USD)
$1.45 / $1.39
+4.51%beat
Revenue / Est. (USD)
9.76B / 9.54B
+2.21%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Oct 2025
Jan 2026
Apr 2026
Jul 2026
Revenue
8.96B
9.02B
9.81B
9.76B
Cost of goods sold
3.06B
3.17B
3.40B
3.41B
Cost of revenue
3.06B
3.17B
3.40B
3.41B
Research and development expenses
754.00M
722.00M
671.00M
771.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.94B
2.93B
3.04B
3.17B
Operating expense
4.08B
4.04B
4.25B
4.46B
Total operating expenses
7.14B
7.21B
7.64B
7.87B
Operating income
1.82B
1.80B
2.16B
1.89B
Other non operating income
3.00M
13.00M
154.00M
33.00M
EBT including unusual items
1.60B
1.40B
1.84B
1.77B
EBT excluding unusual items
1.68B
1.66B
2.16B
1.82B
Income tax expense
215.00M
254.00M
575.00M
289.00M
Effective tax rate
13.47%
18.10%
31.34%
16.35%
Other operating expenses
-29.00M
-79.00M
126.00M
113.00M
Net income
1.37B
1.14B
1.24B
1.47B
Net profit margin
15.33%
12.68%
12.68%
15.07%
Earnings per share
1.36
1.36
1.55
1.45
Interest and investment income
89.00M
102.00M
73.00M
102.00M
Interest expense
-181.00M
-181.00M
-176.00M
-186.00M
Net interest expenses
-92.00M
-79.00M
-103.00M
-84.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.52B
2.52B
2.88B
2.62B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps